… In this trial involving hospitalized patients with mild-to-moderate Covid-19, we did not find a
significant difference in a 15-day ordinal clinical-status outcome among groups that received …

… coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some
promising medication to our patients with mild to moderate … COVID-19 with mild to moderate …

… , adults with early mild-to-moderate COVID-19 were 1:1 randomized to favipiravir or placebo.
The study evaluated time to sustained clinical recovery (TT-SCR), COVID-19 progression, …

… Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with …
of antispike neutralizing antibodies in patients with COVID-19 as a primary end point. …

… cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease
severity, … We identify a major shift between mild and moderate disease, at which point elevated …

… of mild to moderate COVID-19 to severe disease. … Among nonhospitalized patients with mild
to moderate COVID-19 … high-risk patients with mild to moderate COVID-19, although efficacy …

… among mild or moderate COVID-19 patients… COVID-19,” and “efficacy.” This meta-analysis
included studies that compared the effectiveness of molnupiravir with a placebo for COVID-19 …

… in patients with mild to moderate COVID-19 who constitute about 80% of COVID-19 infections
[… of newly diagnosed diabetes in COVID-19 patients with mild to moderate illness. We also …

… have mild-to-moderate COVID-19 disease. Convalescence from mild-to-moderate (MtoM)
COVID-19 … Integrative medicine strategies that may support recovery from MtoM COVID-19 are …

… of COVID‐related symptoms 12‐months after the onset of mild‐to‐moderate disease. … was
created in our region in response to the COVID‐19 pandemic in order to monitor all isolated …